Article
Assessment of thiopurine methyltransferase enzyme activity is superior to genotype in predicting myelosuppression following azathioprine therapy in patients with inflammatory bowel disease.
Alimentary pharmacology & therapeutics - 1 May 2007
Winter J W, Gaffney D, Shapiro D, Spooner R J, Marinaki A M, Sanderson J D, Mills P R
Abstract excerpt
BACKGROUND: Myelosuppression occurs in 2-7% of inflammatory bowel disease (IBD) patients treated with azathioprine, and can be associated with reduced activity of thiopurine methyltransferase (TPMT) in some patients. It has been proposed that pretreatment assessment of TPMT status reduces the incidence of toxicity and is cost-effective. AIMS: To determine if screening for TPMT status predicts side-effects to...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.